Advanced glycation end-products activate the renin-angiotensin system through the RAGE/PI3-K signaling pathway in podocytes

Clinical and Investigative Medicine

Volumn 35, Issue 5, 2012, Pages

  Cheng, Cailan L ^a   Tang, Ying ^a   Zheng, Zhenda D ^a   Liu, Xun ^a   Ye, Zengchun C ^a   Wang, Cheng ^a   Lou, Tanqi Q ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE; IMMUNOGLOBULIN RECEPTOR; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; RENIN;

ANIMAL; APOPTOSIS; ARTICLE; CELL LINE; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; MOUSE; PHYSIOLOGY; PODOCYTE; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANGIOTENSINOGEN; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION END PRODUCTS, ADVANCED; MICE; ONCOGENE PROTEIN V-AKT; PEPTIDYL-DIPEPTIDASE A; PHOSPHATIDYLINOSITOL 3-KINASES; PODOCYTES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, IMMUNOLOGIC; RENIN; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 84872029442     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H . Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991;325:836-842.
2. Pavenstadt H, Kriz W, and Kretzler M. Cell biology of the glomerularpodocyte. Physiol Rev 2003; 83: 253-307.
3. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
4. Gross ML, El-Shakmak A, Szábó A, Koch A, Kuhlmann A, Münter K, Ritz E, Amann K. ACE-inhibitors but not endothelinreceptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 2003; 46: 856-868
5. Singh R, Singh AK, Leehey DJ. A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli. Am J Physiol Renal Physiol 2005;288: F1183-F1190.
6. Singh R, Singh AK, Alavi N, Leehey DJ. Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol 2003; 14: 873-880.
7. Zhang SL, To C, Chen X, Filep JG, Tang SS, Ingelfinger JR, Chan JS. Essential roles of the intrarenal renin-angiotensin system in transforming growth factor-beta1 gene expression and induction of hypertrophy of rat kidney proximal tubular cells in high glucose. J Am Soc Nephrol 2002; 13: 302-312.
8. Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, Pichler R, Griffn S, Couser WG, Shankland SJ. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004;65: 30-39.
9. Coffer PJ, Jin J, Woodgett JR. Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J 1998; 335(Pt 1):1-13
10. Fruman DA, Cantley LC . Phosphoinositide 3-kinase in immunological systems. Semin Immunol 2002;14:7-18
11. Tejada T, Catanuto P, IjazA, Santos JV, Xia X, Sanchez P, Sanabria N, Lenz O, Elliot SJ, Fornoni A. Failure to phosphorylate AKT in podocytes from mice with early diabetic nephropathy promotes cell death. Kidney Int 2008;73 (12): 1385-1393
12. Tae-Sun Ha. High-glucose and advanced glycosylation end products increased podocyte permeability via PI3-K/Akt signaling. J Mol Med 2010; 88:391-400.
13. Kim SH, Jang YW, Hwang P, Kim HJ, Han GY, Kim CW. The Reno-Protective Effect of a PI3K Inhibitor (Wortmannin) on STZ-Induced Proteinuric Renal Disease Rats. Exp Mol Med. 2011 Nov 3. [Epub ahead of print]
14. Ye ZC, Wang C, Tang Y, Liu X, Peng H, Zhang H, Lou TQ. Serum IgA1 from patients with IgA nephropathy up-regulates integrin-linked kinase synthesis and inhibits adhesive capacity in podocytes through indirect pathways. Clin Invest Med 2009; 32(1):E20-7.
15. Cushman DW, Cheung HS. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol 1971;20:1637-48.
16. Bohlender J M, Franke S, Stein G, et al. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005; 289: F645-F659.
17. Wolf G, Butzmann U, and Wenzel UO. The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol 2003;93: 3-13.
18. Yoo TH, Li JJ, Kim JJ, Jung DS, Kwak SJ, Ryu DR, Choi HY, Kim JS, Kim HJ, Han SH, Lee JE, Han DS, Kang SW. Activation of the renin-angiotensin system within podocytes in diabetes. Kidney International 2007;71:1019-1027.
19. Price DA, Porter LE, Gordon M, et al. The paradox of the lowrenin state in diabetic nephropathy J Am Soc Nephrol 1999; 10(11):2382-91.
20. Wang L, Flannery PJ, Spurney RF. Characterization of angiotensin II-receptor subtypes in podocytes. J Lab Clin Med 2003; 142: 313-321.
21. Liebau MC, Lang D, Böhm J, Endlich N, Bek MJ, Witherden I, Mathieson PW, Saleem MA, Pavenstädt H, Fischer KG. Functional expression of the renin angiotensin system in human podocytes. Am J Physiol Renal Physiol 2006; 27: F710-F719.
22. Siragy HM. AT(1) and AT(2) receptors in the kidney: role in disease and treatment. Am J Kidney Dis 2000; 36: S4-S9.
23. Usui M, Egashira K, Kitamoto S, Koyanagi M, Katoh M, Kataoka C, Shimokawa H, Takeshita A. Pathogenic role of oxidative stress in vascular angiotensin-converting enzyme activation in longterm blockade of nitric oxide synthesis in rats. Hypertension 1999;34:546-551.
24. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003;14: 1738-1747.
25. Liebau MC, Lang D, Bohm J, Endlich N, Bek MJ, Witherden I, Mathieson PW, Saleem MA, Pavenstadt H, Fischer KG. Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol Renal Physiol 2006; 290: F710-F719.
26. Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor kappa B, and by 17- beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000;275:25781-25790.
27. Yamagishi S, Amano S, Inagaki Y, Okamoto T, Takeuchi M, Makita Z. Beraprost sodium, a prostaglandin I2 analogue, protects against advanced glycation end products-induced injury in cultured retinal pericytes. Mol Med 2002;8:546-550.
28. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001;108:261-268.
29. Rüster C, Franke S, Wenzel U, et al. Podocytes of AT2 receptor knockout mice are protected from angiotensin II-mediated RAGE induction. Am J Nephrol 2011;34(4):309-17.